Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 5, 2001

View Archived Issues

Nexell awarded orphan drug status for stem cell product

Valentis acquires electroporation technology license from Genetronics

Abgenix licenses novel cancer target for development of potential antibody therapies

Elan highlights oncology portfolio

Encouraging results from phase I study of inhalable leuprolide

Alista associated with positive results in female sexual dysfunction

Affitech and Axaron form strategic alliance for genomics-based antibody drugs

Praecis proceeds with clinical plans for Plenaxis following discussions with the FDA

Research snapshots in neuroprotection

Second approval for first oral drug for the treatment of PAH

Cephalon announces agreement to acquire French pharmaceutical company

Regulatory update on Glivec/Gleevec

Further characterization of the bronchodilating effects of Ro-25-1553 in human preparations

Expression of mda-7 gene downregulated in advanced human melanomas; INGN-241 blocks growth

VNS effective and safe in chronic or recurrent treatment-resistant depression

PH-50: a promising new vascular imaging agent from Photogen

Long-term pegvisomant beneficial in acromegaly

Fusion proteins useful for DC-based immunotherapy of tumors

Delivery of polynucleotides into cells using histones under study at Biogeny

Sankyo discloses new triazole antifungal agents in recent patent

New broad-spectrum antibacterial agents in the GSK pipeline

Antiinflammatory and analgesic effects demonstrated for new PLA2 inhibitors

Cyclooxygenase inhibitors synthesized at Takeda useful for inflammation, pain and fever

Recent patent covers oxytocin receptor ligands identified at Sanofi-Synthelabo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...